Best Practices in the Management of Multiple Sclerosis: Optimizing Clinical and Economic Outcomes in an Evolving Treatment Paradigm

Best Practices in the Management of Multiple Sclerosis: Optimizing Clinical and Economic Outcomes in an Evolving Treatment Paradigm is organized by National Association of Managed Care Physicians (NAMCP).,This activity is valid from August 1, 2022, to August 1, 2023,Description:,Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States, and every week around 200 people are diagnosed with the disease. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies has shown the ability to improve outcomes and quality of life in patient's MS, it makes staying current with best practices a challenge that must be overcome through education. New options showing improved efficacy, safety, and deliverability have recently been approved, which will change the treatment paradigm, and it is for this reason that medical directors, practicing physicians, nurse case managers, and other healthcare professionals must be updated on emerging treatments and strategies in the management of relapsing MS.,Upon completion of this activity, participants will be able to:,• Break down the current treatment challenges and unmet needs in managing multiple sclerosis (MS) and the burden on patients and the healthcare system,• Explore recent clinical data on the efficacy, safety, and dosing/administration of current and emerging MS therapies and their effect on staging and sequencing,• Review current guideline recommendations, evidence-based data, and new and emerging treatment strategies to address unmet needs in MS care,• Compare and contrast S1P therapies for the treatment of relapsing and progressive forms of MS,• Examine the healthcare utilization and costs associated with MS and the managed care considerations in facilitating access to efficacious and individualized treatment,Additional details will be posted as soon as information is available.